Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
24 mars 2023 16h01 HE
|
Bio-Path Holdings, Inc.
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Provides Clinical and Operational Update
16 mars 2023 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, March 16, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
07 déc. 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
15 nov. 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
08 nov. 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
07 nov. 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
24 oct. 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 sept. 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...
Bio-Path Holdings Reports Second Quarter 2022 Financial Results
16 août 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...
Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022
09 août 2022 07h00 HE
|
Bio-Path Holdings, Inc.
HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a...